

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF
ROGER MICHAEL LANE
INTERNATIONAL APPLICATION NO: PCT/EP2005/001715
FILED:
U.S. APPLICATION NO: Not yet known
35 USC §371 DATE:
FOR: USE OF CHOLINESTERASE INHIBITORS FOR TREATING
VASCULAR DEPRESSION

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2005/001715, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Peter J. Waibel', is written over a horizontal line.

Peter J. Waibel
Attorney for Applicant
Reg. No. 43,228

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7951

Date: *August 14, 2006*

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33659-US-PCT
APPLICATION NO.
Not yet known
APPLICANT
ROGER MICHAEL LANE
FILING DATE

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	2005/051297	6/9/05	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Nagy, Christa F. et al., "Concurrent administration of donepezil HC1 and sertraline HC1 in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses", British Journal of Clinical Pharmacology, vol. 58, no. Suppl. 1, pps. 25-33, (2004)
AS	Roman, G C., "Vascular dementia: Changing the paradigm", Current Opinion in Psychiatry 2003 United Kingdom, vol. 16, no. 6, pp.635-641, (2003).
AT	Am. J. Psychiatry, vol. 154, pp. 562-565, (1997).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
33659-US-PCT
APPLICATION NO.
Not yet known
APPLICANT
ROGER MICHAEL LANE
FILING DATE

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Roman, G C, et al., "Subcortical ischaemic vascular dementia", Lancet Neurology, Lancet Publishing Group, London, GB, vol. 1, no. 7, pp.426-436, (2002).
DB	Bentue-Ferrer D et al., "Clinically Significant Drug Interactions with Cholinesterase Inhibitors: A Guide for Neurologists", CNS Drugs, New Zealand, vol. 17, no. 13, pp. 947-963, (2003).
DC	Sheline Yi, Freedland Ke, Carney RM.: "How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Jan; 102(1):54-9", Am Journal of Medicine, vol. 1, no. 102, pp. 54-9, (1997).
DD	Kropp S et al., "Diagnostic steps in possible Alzheimer dementia before starting with new therapeutics", Fortschritte Der Neurologie Psychiatrie, Germany, vol. 68, no. 6, pp. 257-261, (2000).
DE	Farlow M R, "Clinical Pharmacokinetics of Galantamine", Clinical Pharmacokinetics, New Zealand, vol. 42, no. 15, pp. 1383-1392, (2003).
DF	
DG	
DH	
DI	
DJ	
DK	
DL	
DM	
DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.